( OTC-BB:SRNE, OTC-PINK:SRNE )

News from Sorrento Therapeutics, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 28, 2016, 17:56 ET Sorrento Therapeutics, Inc. Secures $75 Million Loan Facility

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments...


Nov 16, 2016, 15:24 ET Sorrento's TNK Therapeutics Subsidiary to Acquire Virttu Biologics

TNK Therapeutics, Inc. ("TNK"), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), has entered into a binding term sheet to...


Nov 14, 2016, 06:00 ET Sorrento Therapeutics to Attend Jefferies and ROTH Investor Conferences

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for...


Nov 08, 2016, 16:20 ET Sorrento Therapeutics Closes Acquisition of Scilex

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento") and Scilex Pharmaceuticals Inc. ("SCILEX") announced today the closing of a transaction by...


Sep 27, 2016, 08:00 ET ARK Animal Health, a Subsidiary of Sorrento Therapeutics, Announces Submission of Two Major Technical Sections of a New Animal Drug Application

 ARK Animal Health, Inc. (ARK), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), has filed the Effectiveness and Target...


Sep 13, 2016, 08:00 ET Sorrento Appoints Miranda Toledano As Executive Vice President of Corporate Development, and President of LA Cell

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an antibody-centric, clinical stage biopharmaceutical company developing new treatments for...


Aug 30, 2016, 16:01 ET Sorrento Therapeutics to Present at Two Upcoming Conferences in New York City

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for...


Aug 15, 2016, 18:34 ET Scintilla Pharmaceuticals, Inc., a Subsidiary of Sorrento Therapeutics, Inc., to Acquire Semnur Pharmaceuticals, Inc. to Further Deepen its Pain Management Pipeline

 Scintilla Pharmaceuticals, Inc. ("Scintilla"), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), has entered into a...


Aug 15, 2016, 09:00 ET Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgene, to Join Sorrento as Chief Medical Officer and President of Clinical Development

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new...


Aug 08, 2016, 09:00 ET Scintilla Pharmaceuticals, a Subsidiary of Sorrento Therapeutics, to Acquire SCILEX Pharmaceuticals to Add a Late-Stage Asset to Bolster its Pain Management Business

 Scintilla Pharmaceuticals, Inc. ("Scintilla"), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), has entered into a...


Aug 02, 2016, 09:00 ET Sorrento to Form Joint Venture with CHA Biotech to Develop and Commercialize Natural Killer Cell Therapies

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new...


Jul 11, 2016, 09:00 ET Sorrento and Servier Enter Into Exclusive Worldwide License and Collaboration Agreement for Development and Commercialization of Anti-PD-1 Antibody

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new...


Jun 08, 2016, 07:00 ET Sorrento Closes $150 Million Private Placement Investments

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for...


Jun 07, 2016, 09:04 ET Sorrento and 3SBio Announce CAR-T Joint Venture in China

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new...


May 09, 2016, 12:32 ET Sorrento Therapeutics engaged advisors for exploring strategic alternatives

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new...


May 02, 2016, 11:24 ET Sorrento closes private placement with Yuhan Corporation

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for...


May 02, 2016, 07:00 ET Sorrento to Present at 2 Upcoming Conferences in New York City

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and...


Apr 05, 2016, 18:42 ET Sorrento Appoints Kevin M. Herde As Chief Financial Officer

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an antibody-centric, clinical stage biopharmaceutical company developing new treatments for...


Mar 14, 2016, 07:00 ET Sorrento to Present at the 28th Annual ROTH Conference

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and associated...


Mar 04, 2016, 07:00 ET Sorrento to Present at the Cowen and Company 36th Annual Health Care Conference

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical-stage oncology company developing new treatments for cancer and...